Carfilzomib represents a novel proteasome inhibitor utilized in the struggle against cancer. It treatment operates by blocking the activity of the proteasome, a cellular machine responsible for the destruction of proteins. By restricting this mechanism, carfilzomib results in the buildup of damaged or abnormal proteins, ultimately causing cell term

Tepotinib, also known as {MSC2156119|the experimental compound|this molecule), represents a promising step in the targeting of non-small cell lung cancer, particularly in those harboring MET changes. This selective tyrosine kinase agent|TKI demonstrates remarkable effect against cancer progression in laboratory evaluations and early-phase clinical

Teclistamab serves as a revolutionary advanced anti-BCMA antibody drug construct, designated JNJ-64007957, demonstrating immense efficacy in the therapy of multiple myeloma. This innovative agent operates by specifically attacking BCMA, a molecule highly present on the surface of myeloma cells. Through this specific approach, teclistamab delivers a